ArticleEuropean journal of nuclear medicine and molecular imaging2025
Texture analysis and metabolic parameters of
Article in European journal of nuclear medicine and molecular imaging, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The predictive value ofFrontiers in medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionWe aimed to investigate the value of primary tumour F-18 fluorodeoxyglucose ( MATERIALS AND
methodsTwenty-eight paediatric patients with STS who underwent
resultsIn univariate analysis SUVmax > 13.0 (p = 0.009), SUVpeak > 12.7 (p = 0.017), Histogram Entropy > 0.97 (p = 0.036), and NGTDM Busyness < 0.37 (p = 0.005) were associated with tumour response for the median follow-up of 25 months. NGTDM Busyness was an independent predictor for the treatment response (OR: 30.5; 95% CI: 1.50-618.5; p = 0.026). Age was associated with progression (Cut-off: 11 years, [AUC:0.73 (95% CI: 0,53 - 0,93)] 𝑝=0.022). Progression-free survival outcomes were assessed in aged > 11 years subpopulation. PFS was significantly shorter in patients with high GLSZM_GLNU (p = 0,024), GLSZM_ZSNU (p = 0,003), and TLG (p = 0,016). In multivariate analysis GLSZM_ZSNU > 13,04 (HR: 11.61; 95% CI: 1.35-54.02; p = 0.026) was an independent predictor of PFS in subpopulation aged > 11 years.
conclusionHeterogeneity texture features Histogram Entropy and NGTDM Busyness and metabolic PET parameters (SUV max and SUVpeak) can predict tumour response. In aged > 11 years patients subgroup analyses, GLSZM ZSNU was an independent factor for PFS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.